Redeye comments on NextCell ahead of the ProTrans-Young Phase II readout expected in September. The data cut covers one-year results for the full 60-patient trial population and two-year results for the older cohort. The latter offers insight into whether the "honeymoon effect" could explain last year's inconclusive interim.
LÄS MER
